K145 hydrochloride

CAS No. 1449240-68-9

K145 hydrochloride( —— )

Catalog No. M29603 CAS No. 1449240-68-9

K145 hydrochloride is a selective sphk2 inhibitor with substrate competitiveness and oral activity, with IC50 of 4.3 μM and Ki of 6.4 μM. K145 hydrochloride can induce apoptosis and has strong antitumor activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 45 In Stock
10MG 61 In Stock
25MG 87 In Stock
50MG 122 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    K145 hydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    K145 hydrochloride is a selective sphk2 inhibitor with substrate competitiveness and oral activity, with IC50 of 4.3 μM and Ki of 6.4 μM. K145 hydrochloride can induce apoptosis and has strong antitumor activity.
  • Description
    K145 hydrochloride is a selective sphk2 inhibitor with substrate competitiveness and oral activity, with IC50 of 4.3 μM and Ki of 6.4 μM. K145 hydrochloride can induce apoptosis and has strong antitumor activity.(In Vitro):K145 hydrochloride inhibited the activity of SphK2 in a dose-dependent manner with an IC50 of 4.30 μM. The Lineweaver-Burk analysis revealed a Ki of 6.4±0.7 μM for SphK2 and indicated that K145 hydrochloride is a substrate competitive inhibitor (with sphingosine). K145 hydrochloride accumulates in U937 cells, suppresses the S1P level, and inhibits SphK2. K145 hydrochloride also exhibited inhibitory effects on the growth of U937 cells as well as apoptotic effects in U937 cells, and that these effects may be through the inhibition of downstream ERK and Akt signaling pathways.(In Vivo):In BALB/c-nu mice injected with U937 cells, K145 hydrochloride (50 mg/kg; oral gavage; for 15 days) treatment significantly inhibited the growth of U937 tumors at 50 mg/kg dose and no apparent toxicity was observed.
  • In Vitro
    K145 (0-10 μM; 24-72 hours; U937 cells) treatment significantly inhibits the growth of U937 cells in a concentration-dependent manner.K145 (10 μM; 24 hours; U937 cells) treatment significantly induces apoptosis in U937 cells.K145 (4-8 μM; 3 hours; U937 cells) treatment decreases the phosphorylation of ERK and Akt.Treatment with K145 (10 μM) causes a decrease of total cellular S1P without significant effects on ceramide levels. Cell Viability Assay Cell Line:U937 cells Concentration:0 μM, 4 μM, 6 μM, 8 μM, 10 μM Incubation Time:24 hours, 48 hours, 72 hours Result:Significantly inhibited the growth of U937 cells in a concentration-dependent manner.Apoptosis Analysis Cell Line:U937 cells Concentration:10 μM Incubation Time:24 hours Result:Significantly induced apoptosis in U937 cells.Western Blot Analysis Cell Line:U937 cells Concentration:4 μM, 8 μM Incubation Time:3 hours Result:Phosphorylated ERK and Akt were decreased.
  • In Vivo
    K145 (50 mg/kg; oral gavage; daily; for 15 days; BALB/c-nu mice) treatment significantly inhibits the growth of U937 tumors in nude mice. Animal Model:BALB/c-nu mice injected with U937 cells Dosage:50 mg/kg Administration:Oral gavage; daily; for 15 days Result:Inhibited the growth of U937 tumors at 50 mg/kg dose and no apparent toxicity was observed.
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    Apoptosis
  • Recptor
    Apoptosis
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1449240-68-9
  • Formula Weight
    384.92
  • Molecular Formula
    C18H25ClN2O3S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?H2O : 126.7 mg/mL (329.16 mM)
  • SMILES
    Cl.CCCCOc1ccc(CC\C=C2/SC(=O)N(CCN)C2=O)cc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • SACLAC

    SACLAC is a cysteine asparaginase activation inhibitor with antitumor activity that decreases AML cell viability, inhibits AML cell proliferation, increases AML cell death, and induces apoptosis of AML cells, and is used in the study of acute myeloid leukemia and cancer.

  • AAPK-25

    AAPK-25, a potent and selective dual inhibitor of Aurora/PLK, causes mitotic delay and cell arrest in prometaphase, via phosphorylation of the biomarker histone H3Ser10, followed by a surge in apoptosis.

  • LAT1-IN-1

    LAT1-IN-1 (BCH) ?significantly inhibit cellular uptake of amino acids and mTOR phosphorylation, which induces the suppression of cancer growth and apoptosis.?